Tsion Abay

Mar 25, 2024 | protocols.io | Tsion Abay |Robert R. Stickels |Caleb A Lareau

protocols.io requires JavaScript to be enabled in the browser.

Dec 22, 2023 | science.org | Tsion Abay |Jackie Oberst

For many years, the study of neurological conditions such as Parkinson’s disease, Alzheimer’s disease, and ALS, as well as the process of neurological recovery following spinal injuries or strokes, has been hindered by a lack of accurate models. Traditional research often relies on postmortem brain samples, which may not be well-preserved and typically reflect the final stages of disease. Rodent models also fall short in mimicking the complexity of human neural characteristics.

Nov 8, 2023 | nature.com | Caleb A Lareau |Yajie Yin |Katie Maurer |Katalin Sandor |Bence Daniel |Jose Sanz Peña | +20 more

AbstractCell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1.